Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 7/20 | 0.38 |
| ▸ | OGG1 | O15527 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17256193 | 0.85 | LOXL2 (0.54) | LOXL2MCL1PTGER4OGG1HDAC1 | |
| SCHEMBL13014899 | 0.81 | HRH1 (0.36) | LOXL2MCL1CYP3A4CYP2D6HRH1 | |
| SCHEMBL11886897 | 0.77 | LOXL2 (0.51) | LOXL2MCL1PTGER4OGG1HDAC1 | |
| SCHEMBL17921221 | 0.75 | LOXL2 (0.65) | LOXL2MCL1OGG1HDAC1HDAC8 | |
| SCHEMBL662349 | 0.73 | LOXL2 (0.41) | LOXL2PTGER4CD274MEN1ALDH1A1 | |
| SCHEMBL660485 | 0.72 | LOXL2 (0.61) | LOXL2MCL1OGG1HDAC1HDAC8 | |
| SCHEMBL1254026 | 0.72 | LOXL2 (0.76) | LOXL2MCL1OGG1HDAC1HDAC8 | |
| SCHEMBL27296293 | 0.72 | LOXL2 (0.65) | LOXL2MCL1OGG1HDAC1HDAC8 | |
| SCHEMBL658865 | 0.71 | LOXL2 (0.69) | LOXL2MCL1OGG1HDAC1HDAC8 | |
| SCHEMBL5309758 | 0.70 | LOXL2 (0.38) | LOXL2PTGER4CD274MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2803358-B1 | 10,10-Dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure | ALLERGAN INC (US) | 2017-05-03 | — | — | EP | disclosed |
| US-9637467-B2 | Treatment of inflammatory bowel disease | ALLERGAN, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-9334262-B2 | Methods of treating soft tissue defects | ALLERGAN, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20160096817-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | ALLERGAN, INC. | 2016-04-07 | — | — | US | disclosed |
| US-9156810-B2 | Treatment of inflammatory bowel disease | ALLERGAN, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-9005605-B2 | Compositions and soft tissue replacement methods | ALLERGAN, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-8926963-B2 | Compositions and soft tissue replacement methods | ALLERGAN, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| EP-2814527-A1 | COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS | ALLERGAN, INC. (US) | 2014-12-24 | — | — | EP | disclosed |
| EP-2814510-A1 | COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS | ALLERGAN, INC. (US) | 2014-12-24 | — | — | EP | disclosed |
| EP-2814526-A1 | COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS | ALLERGAN, INC. (US) | 2014-12-24 | — | — | EP | disclosed |
| WO-2006058063-A1 | 2,3,4-SUBSTITUTED-CYCLOPENTANONES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2006-06-01 | — | — | WO | disclosed |
| WO-2006055481-A1 | 2,3,4-SUBSTITUTED CYCLOPENTANONES AS THERAPEUTIC AGENTS | ALLERGAN , INC. (US) | 2006-05-26 | — | — | WO | disclosed |
| US-20060111430-A1 | 2,3,4-substituted cyclopentanones as therapeutic agents | ALLERGAN, INC. (US) | 2006-05-25 | — | — | US | disclosed |
| US-20060106088-A1 | 2,3,4-Substituted cyclopentanones as therapeutic agents | ALLERGAN, INC. (US) | 2006-05-18 | — | — | US | disclosed |
| EP-1608309-A2 | 10,10-DIALKYL PROSTANOIC ACID DERIVATIVES AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | Allergan, Inc. (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20050164992-A1 | Treating inflammatory bowel disease by administering prostaglandin derivatives such as (3-{(1R,4S,5S)-5-(3-chloro-benzo[b]thiophen-2-yl)-3-hydroxy-pent-1-enyl]-4-hydroxy-3,3-dimethyl-2-oxo-cyclopentylsulfanyl}-propylsulfanyl)-acetic acid methyl ester | ALLERGAN, INC. (US) | 2005-07-28 | — | — | US | disclosed |
| US-6875787-B2 | 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure | ALLERGAN, INC. (US) | 2005-04-05 | — | — | US | disclosed |
| US-20040235958-A1 | 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure | ALLERGAN, INC. | 2004-11-25 | — | — | US | disclosed |
| WO-2004071428-A2 | 10,10-DIALKYL PROSTANOIC ACID DERIVATIVES AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN, INC. (US) | 2004-08-26 | — | — | WO | disclosed |
| US-20040157901-A1 | 10,10-DIALKYL PROSTANOIC ACID DERIVATIVES AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN, INC. | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096817-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | SLC10A2, FABP2, LTB4R2 | LOXL2 1207/4885MCL1 4416/4885PTGER4 228/4885 |
| US-20050164992-A1 | Treating inflammatory bowel disease by administering prostaglandin derivatives such as (3-{(1R,4S,5S)-5-(3-chloro-benzo[b]thiophen-2-yl)-3-hydroxy-pent-1-enyl]-4-hydroxy-3,3-dimethyl-2-oxo-cyclopentylsulfanyl}-propylsulfanyl)-acetic acid methyl ester | PTGER1, PTGES, PTGS1 | LOXL2 378/4885MCL1 4166/4885PTGER4 15/4885 |
| US-20060111430-A1 | 2,3,4-substituted cyclopentanones as therapeutic agents | CYP11B2, CYP11B1, CYP4A11 | LOXL2 1464/4885MCL1 1020/4885PTGER4 391/4885 |
| US-20060106088-A1 | 2,3,4-Substituted cyclopentanones as therapeutic agents | CYCS, CA6, COX6C | LOXL2 1496/4885MCL1 601/4885PTGER4 663/4885 |
| US-20040157901-A1 | 10,10-DIALKYL PROSTANOIC ACID DERIVATIVES AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | PTGIR, CBR1, DECR1 | LOXL2 429/4885MCL1 4180/4885PTGER4 85/4885 |
| US-20040235958-A1 | 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure | PTGIR, CBR1, DECR1 | LOXL2 382/4885MCL1 4036/4885PTGER4 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.